Priothera

Priothera
Priothera
Priothera is a clinical-stage company developing orally applied sphingosine 1 phosphate (S1P) receptor modulators for hematological malignancies. We are dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of allogeneic HematopoieticStem Cell Transplantation (HSCT) in these patients.
Dublin
clinical-stage, hematological, sphingosine
Above €25 million
2020
https://priothera.com/

Articles about Priothera:

💡 You’re a corporate or investor and looking for startups that are innovating in the same market as Priothera? We’re happy to assist you with our Startup Sourcing service.